Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Ovarian Neoplasms

  Free Subscription


20.01.2020

2 Am J Obstet Gynecol
2 Br J Cancer
1 Cancer
2 Cancer Res
5 Gynecol Oncol
2 Int J Cancer
1 Lancet Oncol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Obstet Gynecol

  1. GIBBS J, Mei S, Economos K, Lee YC, et al
    Clinicopathologic features, incidence and survival trends of gynecologic neuroendocrine tumors; a SEER data base analysis.
    Am J Obstet Gynecol. 2019 Mar 5. pii: S0002-9378(19)30431.
    PubMed     Text format     Abstract available

  2. OKAZAKI A, Nishi K, Kasahara K
    Pseudo-Meigs Syndrome Caused by Cancer of the Uterine Corpus.
    Am J Obstet Gynecol. 2018 Dec 7. pii: S0002-9378(18)32217.
    PubMed     Text format    


    Br J Cancer

  3. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Text format     Abstract available

  4. HORIKAWA N, Abiko K, Matsumura N, Baba T, et al
    Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0725.
    PubMed     Text format     Abstract available


    Cancer

  5. PRINTZ C
    Study finds that women with posttraumatic stress disorder have an increased risk of ovarian cancer.
    Cancer. 2020;126:468-469.
    PubMed     Text format    


    Cancer Res

  6. TRABERT B, Tworoger SS, O'Brien KM, Townsend MK, et al
    The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3).
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-2850.
    PubMed     Text format     Abstract available

  7. ASEM M, Young AM, Oyama C, Claure De La Zerda AG, et al
    Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-1601.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  8. FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
    High homogeneity of MMR deficiency in ovarian cancer.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
    PubMed     Text format     Abstract available

  9. MONK BJ, Herzog TJ, Wang G, Triantos S, et al
    A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
    PubMed     Text format     Abstract available

  10. STALEY SA, Tucker K, Newton M, Ertel M, et al
    Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
    PubMed     Text format     Abstract available

  11. MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
    Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
    PubMed     Text format     Abstract available

  12. BIXEL K, Vetter M, Davidson B, Berchuck A, et al
    Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
    PubMed     Text format     Abstract available


    Int J Cancer

  13. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    PubMed     Text format     Abstract available

  14. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    PubMed     Text format     Abstract available


    Lancet Oncol

  15. GOURD E
    Olaparib plus bevacizumab improves progression-free survival in ovarian cancer.
    Lancet Oncol. 2020 Jan 9. pii: S1470-2045(20)30005.
    PubMed     Text format    


    PLoS One

  16. ZHAO Y, Mehta M, Walton A, Talsania K, et al
    Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas.
    PLoS One. 2019;14:e0216050.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: